Change at the top for Phathom as Basta replaces Curran
Plus: Updates from Nuage, GV, Inhibrx, Lyell, Repare, Adcendo, ITM Isotope, Transgene and Novartis
Phathom Pharmaceuticals Inc. (NASDAQ:PHAT) said President and CEO Terrie Curran is stepping down for personal reasons and resigning from the company’s board. The gastrointestinal therapeutics developer named Steven Basta as Curran’s successor; Basta has been CEO of anti-infectives company Sanotize Research and Development Corp., digital therapies company Mahana Therapeutics Inc., and Menlo Therapeutics Inc., now known as immunology company Vyne Therapeutics Inc.
Barcelona-based oncology play Nuage Therapeutics S.L. named Stuart Hughes CEO, and appointed Vanessa Malier as chair of its board. Hughes arrives from immuno-oncology company Pathios Therapeutics Ltd. Malier, a former managing partner at Kurma Partners, was initially a strategic adviser to Nuage before joining as executive chair in April 2024...